STOCKHOLM, Feb. 25, 2020 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) invites investors, analysts and the
media to a R&D Day in Stockholm, Monday March
2, 2020, at 14:00 to 16:30
CET.
The presentations will, among other things, address new clinical
results from the phase Ia study with MIV-818 in liver cancer
patients. Members of Medivir's management team and Professor
Jeff Evans, Director of the
Institute of Cancer Sciences at the University
of Glasgow, will give presentations.
The meeting will be held at Helio GT30, Grev Turegatan 30 in
Stockholm, on March 2 at 14:00 to 16:30
CET.
The presentations will be held in English. The event will also
be streamed via a link on the website: www.medivir.com. The
presentations will be available on Medivir's website.
To register, please send an e-mail to: info@cordcom.se
|
Agenda
|
|
|
|
13.30-14.00
|
Registration and
coffee
|
|
|
14.00-14.10
|
Introduction
|
Dr Uli Hacksell, CEO
Medivir
|
|
14.10-14.40
|
Hepatocellular
carcinoma (and ihCCA) - unmet needs
|
Prof Jeff Evans,
University of Glasgow
|
|
14.40-15.00
|
The liver cancer
market
|
Dr Christina Herder,
COO and EVP, Medivir
|
|
15.00-15.15
|
Break
|
|
|
15.15-15.30
|
The nucleotide
prodrug platform and scientific rationale for MIV-818
|
Dr Fredrik Öberg, CSO
Medivir
|
|
15.30-16.10
|
Current status of the
development of MIV-818
|
Dr Karin Tunblad,
MIV-818 project leader
|
|
16.10-16.30
|
Summing up
|
Dr Uli Hacksell, CEO
Medivir
|
|
16.30-17.30
|
Mingel
|
|
|
Warm
welcome!
|
About MIV-818
MIV-818 is a pro-drug designed to selectively treat liver
cancers and to minimize side effects. It has the potential to
become the first liver-targeted, orally administered drug to
benefit patients with HCC and other forms of liver cancer. A phase
I study is ongoing in liver cancer patients.
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development is conducted
either by Medivir or in partnership. Medivir's share (ticker: MVIR)
is listed on Nasdaq Stockholm's Small Cap list.
www.medivir.com.
For further information, please contact:
Uli
Hacksell, CEO
Medivir AB
Phone: +46(0)8-5468-3100.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/invitation-to-medivir-s-r-d-day-on-march-2--2020,c3045131
The following files are available for download:
|
https://mb.cision.com/Main/652/3045131/1200447.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/invitation-to-medivirs-rd-day-on-march-2-2020-301010462.html
SOURCE Medivir
